Depo-Provera lawsuit claims are growing rapidly across the United States. Thousands of women allege that Pfizer’s injectable contraceptive caused them to develop meningioma brain tumors. As of May 2026, more than 3,700 cases are pending in federal court. The Depo-Provera lawsuit centers on Pfizer’s alleged failure to warn patients about the tumor risk. If you received Depo-Provera injections and were later diagnosed with a meningioma, you may qualify for compensation.
Case Timeline
Last checked: July 10, 2026
Advertisement
July 10, 2026: Pfizer’s Depo-Provera Settlement: What Women With Meningioma Need to Know About the June 2026 Agreement – JD Supra (JD Supra)
July 10, 2026 (Settlement): Pfizer and plaintiffs’ lead counsel reached a global settlement in principle in MDL-3140 on June 15, 2026, per an order from U.S. District Judge M. Casey Rodgers (N.D. Fla.), though no financial terms have been disclosed. (Court Record)
July 10, 2026 (Bellwether Date): The first bellwether trial, Toney v. Pfizer, previously set for December 7, 2026, had its deadlines vacated following the settlement in principle. (Court Record)
July 10, 2026 (Ruling): The general-causation Daubert hearing was reset from June 24-26 to July 27, 2026, to address reliability of plaintiffs’ scientific evidence for cases outside the settlement. (Court Record)
July 10, 2026 (Case Status): Pending MDL cases rose to 5,508 (5,590 filed) per the June 2026 JPML report, with July 2026 totals reported above 5,800; the settlement does not affect ongoing state-court filings. (Court Record)
July 03, 2026 (Settlement): Pfizer and plaintiffs reached an agreement in principle on June 17, 2026 for a global settlement resolving the federal Depo-Provera MDL-3140, with compensation details still being finalized. (Court Record)
July 03, 2026 (Bellwether Date): The first bellwether trial (Toney v. Pfizer), previously set for December 7, 2026, has been taken off the calendar following the tentative global settlement. (Court Record)
July 03, 2026 (Ruling): Daubert hearings on general causation were held June 24–26, 2026, with a ruling from Judge Casey Rodgers (N.D. Fla., the presiding judge) on the preemption defense still pending. (Court Record)
July 03, 2026 (Other): The MDL is presided over by Judge M. Casey Rodgers in the Northern District of Florida — not Judge Michael J. Davis (D. Minn.) as referenced in the request. (Court Record)
July 02, 2026: New Evidence Links Progestogen Contraceptives to Brain Tumor Risk – MedPage Today (MedPage Today)
June 30, 2026: Pfizer Reaches Tentative Settlement in Depo-Provera Cases, Bellwether Trial Vacated – Law.com (Law.com)
June 30, 2026: Her Case Matters Explains the Upcoming June 24 Depo-Provera(R) Hearing for Women Who Trusted the Birth Control – reflector.com (reflector.com)
June 16, 2026: Depo-Provera Settlement (2026): Payouts & Eligibility – Drugwatch.com (Drugwatch.com)
June 26, 2026 (Settlement): In June 2026, Pfizer and plaintiffs’ lawyers agreed to a global settlement in MDL-3140, though compensation amounts and terms are still being finalized. (Court Record)
June 26, 2026 (Bellwether Date): The first bellwether trial (Blonski v. Pfizer, with Toney v. Pfizer also referenced) remains scheduled for December 7, 2026, the first of five planned bellwethers. (Court Record)
June 26, 2026 (Ruling): A 3-day Daubert hearing on the admissibility of plaintiffs’ expert causation testimony is set for June 24-26, 2026 before Judge M. Casey Rodgers. (Court Record)
June 26, 2026 (Ruling): Judge Rodgers is currently reviewing Pfizer’s preemption motion, a decision that could significantly shape the trajectory of the entire litigation. (Court Record)
June 26, 2026 (Case Status): As of June 1, 2026, there are 5,508 pending actions in MDL-3140 (plus ~332 in Delaware, 72 in New York, 21 in California), up over 5,700% since the MDL was created in February 2025. (Court Record)
June 26, 2026 (Other): The FDA approved an updated Depo-Provera CI meningioma warning instructing discontinuation if meningioma is diagnosed, undercutting Pfizer’s prior failure-to-warn preemption argument. (Court Record)
June 22, 2026: Pfizer reaches agreement to resolve Depo-Provera brain tumor MDL – Class Action Lawsuits (Class Action Lawsuits)
June 19, 2026: Depo-Provera Birth Control Shot Lawsuit | 2026 Settlement Update – Consumer Notice (Consumer Notice)
June 16, 2026: Depo-Provera Settlement Could Resolve Thousands of Brain Tumor Lawsuits – Drugwatch.com (Drugwatch.com)
June 15, 2026: Depo-Provera Brain Tumor MDL Adds 1,700 Cases in 1 Month – The Legal Examiner (The Legal Examiner)
June 15, 2026: Depo-Provera Lawsuit Settlement Agreement May Resolve Eligible Meningioma Claims in MDL – AboutLawsuits.com (AboutLawsuits.com)
June 12, 2026 (Bellwether Date): First bellwether trial (Blonski v. Pfizer) scheduled for December 7-14, 2026, with five pilot trials planned through early 2027. (Court Record)
June 12, 2026 (Ruling): Daubert/Rule 702 hearings on general causation experts held May 26-28, 2026; second round scheduled June 24-26, 2026. (Court Record)
June 12, 2026 (Ruling): Federal preemption ruling from Judge M. Casey Rodgers (N.D. Fla.) still pending — could dismiss or advance all cases. (Court Record)
June 12, 2026 (Case Status): Case count surged to over 5,500 federal filings as of June 2026, up ~50% since March 2026; plus 439 state-court actions. (Court Record)
June 12, 2026 (Other): Case Management Conference scheduled for June 26, 2026 at 9:00 a.m. CT. (Court Record)
June 12, 2026 (Other): MDL plaintiff leadership reappointed (Tracy Finken as Executive Committee Co-Chair). (Court Record)
June 12, 2026 (Settlement): No global settlement framework announced; estimated individual settlement values range $150K–$1.5M depending on severity. (Court Record)
December 16, 2025: FDA approves label change for Depo-Provera, adding brain tumor warning – NBC News (NBC News)
April 02, 2026: Depo-Provera and Meningioma: What the Latest Research Means for Women Who Used the Birth Control Shot – JD Supra (JD Supra)
June 02, 2026: Depo-Provera Statistics | Depo Shot Facts & Figures (2026) – Sokolove Law (Sokolove Law)
June 05, 2026: Depo-Provera Meningioma Side Effects Left Woman With Debilitating Migraines, Lawsuit Claims – AboutLawsuits.com (AboutLawsuits.com)
June 05, 2026 (Ruling): Daubert hearing on general causation experts held May 26-28, 2026; Rule 702 motions hearing scheduled June 24-26, 2026 — ruling from Judge M. Casey Rodgers expected afterward. (Court Record)
June 05, 2026 (Ruling): Judge Rodgers is expected to rule on Pfizer’s preemption defense in 2026; if it fails, it removes Pfizer’s strongest legal shield and could accelerate settlement talks. (Court Record)
June 05, 2026 (Case Status): Case count has grown to approximately 3,769 pending lawsuits as of May 2026, a 3,873% increase from March 2025 (78 cases to 3,099+ in one year). (Court Record)
June 05, 2026 (Other): In December 2025, the FDA approved a new meningioma warning on Depo-Provera’s U.S. label, significantly impacting Pfizer’s preemption arguments. (Court Record)
June 05, 2026 (Settlement): No large-scale settlement framework has been announced as of June 2026; attorneys project individual settlement ranges from $75,000 to $1.5 million depending on case severity. (Court Record)
June 05, 2026 (Other): MDL leadership roles were reappointed — plaintiff steering committee confirmed under Judge Rodgers (N.D. Fla.), not Judge Michael J. Davis (D. Minn.) as previously noted; the MDL is in the Northern District of Florida. (Court Record)
June 03, 2026: Pfizer Brought into a Depo-Provera Meningioma Claim in Clark County, WA – The National Law Review (The National Law Review)
June 01, 2026: Depo-Provera Frequently Asked Questions (2026) – Sokolove Law (Sokolove Law)
October 13, 2025: Could This Birth Control Shot Increase Your Risk for Brain Tumor? – UC San Francisco (UC San Francisco)
June 01, 2026: Depo-Provera: Risks, FDA Warnings and Legal Concerns – Drugwatch.com (Drugwatch.com)
May 28, 2026: Depo-Provera Side Effects: What To Know After Long-Term Use – Drugwatch.com (Drugwatch.com)
May 01, 2026: Who Can Sue Depo-Provera? Depo Shot Lawsuit Eligibility in 2026 – Sokolove Law (Sokolove Law)
May 29, 2026: Depo-Provera Lawsuit (May 2026) Who Qualifies & How to File – Drugwatch.com (Drugwatch.com)
May 05, 2026: Depo-Provera Meningioma Lawsuits: Eight Groups of Women Who May Qualify – JD Supra (JD Supra)
May 27, 2026: Depo-Provera Litigation Explained: What Women Should Know About Emerging Brain Tumor Claims – KHTS Radio (KHTS Radio)
May 22, 2026: Depo-Provera Caused Meningioma 29 Years After First Birth Control Shots: Lawsuit – AboutLawsuits.com (AboutLawsuits.com)
May 22, 2026 (Bellwether Date): First bellwether trial (Toney v. Pfizer) is scheduled for December 7–14, 2026, before Judge M. Casey Rodgers in the Northern District of Florida; five pilot cases selected: Toney, Blonski, Schmidt, Wilson, and Arceo. (Court Record)
May 22, 2026 (Ruling): Daubert hearings on general causation expert testimony are scheduled for June 24–26, 2026; ruling will determine whether plaintiffs’ experts can testify at trial. (Court Record)
May 22, 2026 (Settlement): No Depo-Provera settlement has been announced as of May 2026; attorney projections range from $150,000 to $1.5 million per case depending on severity. (Court Record)
May 22, 2026 (Case Status): MDL-3140 has grown to approximately 3,769 pending cases as of May 2026, up from 78 in March 2025 — a 3,873% increase — with ~650 new filings per month. (Court Record)
May 22, 2026 (Other): Presiding judge is M. Casey Rodgers (N.D. Fla.), not Michael J. Davis (D. Minn.); leadership was reappointed with Tracy Finken as Executive Committee co-chair. (Court Record)
May 22, 2026 (Other): Additional bellwether trials are expected to follow in 2027 if no settlement is reached after the December 2026 trial. (Court Record)
May 20, 2026: Birth Injury Justice Center Responds to Rapidly Expanding Depo-Provera Brain Tumor Litigation – ACCESS Newswire (ACCESS Newswire)
May 18, 2026: Depo-Provera Lawsuit Filings Exceed 6,000, As Court Prepares for First Test Trials – AboutLawsuits.com (AboutLawsuits.com)
May 04, 2026: Depo-Provera Lawsuit: 2026 Brain Tumor Claims – Motley Rice (Motley Rice)
May 15, 2026 (Bellwether Date): First bellwether trial (Toney v. Pfizer) scheduled for December 7, 2026, with five pilot cases selected: Toney, Blonski, Schmidt, Wilson, and Arceo. (Court Record)
May 15, 2026 (Ruling): Daubert hearing on general causation experts originally set May 26-28, 2026 has been rescheduled to June 24-26, 2026 before Judge M. Casey Rodgers (N.D. Fla.). (Court Record)
May 15, 2026 (Ruling): Federal preemption ruling still pending — Pfizer’s defense was undermined after FDA approved a meningioma warning label in December 2025, prompting Judge Rodgers to order supplemental briefing. (Court Record)
May 15, 2026 (Ruling): Court confirmed that upcoming preemption and Daubert rulings will apply across the entire MDL, not just the five pilot cases — if Pfizer wins preemption, the MDL effectively ends. (Court Record)
May 15, 2026 (Ruling): Plaintiff leadership reappointed in January 2026 (Pretrial Order No. 29), with Tracy Finken reappointed as Executive Committee co-chair. (Court Record)
May 15, 2026 (Case Status): MDL case count surged to approximately 3,490 pending lawsuits as of April 2026, up from 78 cases in March 2025 — a 3,873% increase. (Court Record)
May 15, 2026 (Settlement): No global settlement has been announced; attorneys expect settlement negotiations to begin after the December 2026 bellwether verdict. (Court Record)
May 15, 2026 (Other): MDL status hearings scheduled throughout 2026; presiding judge is Hon. M. Casey Rodgers (N.D. Fla.), not Judge Michael J. Davis (D. Minn.). (Court Record)
What Is the Depo-Provera Lawsuit About?
| MDL Detail |
Current Data |
| MDL Number |
MDL-3140 |
| Pending Cases |
3,769 |
| Presiding Judge |
Michael J. Davis |
| Federal District |
D. Minn. |
| Data Source |
U.S. Judicial Panel on Multidistrict Litigation |
| Last Updated |
June 01, 2026 |
Depo-Provera is an injectable birth control shot manufactured by Pfizer. It contains medroxyprogesterone acetate (MPA), a synthetic progestin hormone. Millions of women have received the shot since its FDA approval in 1992. The injection is given once every three months. It was widely prescribed as a convenient alternative to daily birth control pills.
However, scientific research has linked long-term Depo-Provera use to meningioma brain tumors. A major 2024 study published in The BMJ found a fivefold increased risk. Meningiomas are tumors that grow in the membranes surrounding the brain and spinal cord. While often classified as benign, they can cause serious symptoms. These include headaches, vision loss, seizures, and cognitive impairment. Some patients require surgery to remove the tumor.
On December 12, 2025, the FDA approved updated warning labels for Depo-Provera. The new label states that meningioma cases have been reported following repeated use. Plaintiffs in the Depo-Provera lawsuit argue that Pfizer knew about this risk for years. They claim the company failed to adequately warn doctors and patients. As a result, many women continued receiving injections without understanding the danger.
MDL Case Status and Key Facts
| Detail |
Information |
| MDL Number |
3140 |
| Full Case Name |
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation |
| Presiding Judge |
Hon. M. Casey Rodgers |
| Federal District |
Northern District of Florida |
| Pending Cases |
Approximately 3,769 (May 2026) |
| Defendant |
Pfizer Inc. |
| Daubert Hearings |
June 24–26, 2026 |
| First Bellwether Trial |
December 7, 2026 (Blonski v. Pfizer) |
| Additional Trials |
Four more scheduled for January 2027 |
The Depo-Provera lawsuit was consolidated into MDL 3140 in the Northern District of Florida. Judge M. Casey Rodgers oversees all federally filed cases. New cases are being filed at a rate of roughly 650 per month. In most cases, the claims allege failure to warn and negligence against Pfizer.
Several critical milestones are approaching in 2026. Daubert hearings on general causation are set for June 24–26, 2026. During these hearings, the court will decide whether plaintiffs’ expert testimony is scientifically reliable. If the court rules favorably, the first bellwether trial begins December 7, 2026. Pfizer has also filed a federal preemption motion. That motion is fully briefed and awaiting the judge’s ruling.
Who Qualifies for the Depo-Provera Lawsuit?
To join the Depo-Provera lawsuit, you typically must meet several criteria. First, you must have received Depo-Provera, Depo-SubQ Provera 104, or an authorized generic version. Second, you must have been diagnosed with a meningioma brain or spinal tumor. In most cases, claimants used the injection for one year or longer. However, women who received at least two injections may also qualify.
Medical records are critical to building your claim. You will need documentation showing your Depo-Provera prescriptions and injection dates. You will also need records confirming your meningioma diagnosis. For example, MRI results, surgical reports, and pathology findings strengthen your case. The timing between your last injection and diagnosis matters as well.
It is important to act quickly. The statute of limitations ranges from one to six years depending on your state. However, the discovery rule may extend this deadline. This rule starts the clock when you first learned about the link between Depo-Provera and brain tumors. A licensed attorney can evaluate your specific timeline and determine whether you might be eligible to file.
How to File a Depo-Provera Lawsuit Claim
Filing a Depo-Provera lawsuit claim begins with a free case evaluation. Most mass tort attorneys offer no-cost consultations. They typically work on a contingency fee basis. This means you pay nothing upfront. Your attorney collects a fee only if you receive compensation.
After retaining a lawyer, your case will be filed in federal or state court. Federal cases are transferred to MDL 3140 in Florida for pretrial proceedings. Your attorney will gather your medical records and pharmacy history. You will also complete a plaintiff fact sheet. This document details your Depo-Provera use, diagnosis, and injuries.
Typically, you do not need to travel to Florida for MDL proceedings. Your attorney handles all filings and court appearances remotely. If your case is selected for a bellwether trial, additional preparation may be needed. Otherwise, your claim proceeds through discovery alongside thousands of others. Consulting a licensed attorney is the essential first step in this process.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Settlement Updates and What to Expect
As of May 2026, no global settlement has been reached in the Depo-Provera lawsuit. Pfizer has not offered a settlement framework to resolve these claims. This is typical for mass tort litigation at this stage. Settlement negotiations usually begin after bellwether trial results provide both sides with meaningful data.
The first bellwether trial — Blonski v. Pfizer — is scheduled for December 7, 2026. Four additional trials follow in January 2027. These early verdicts will heavily influence future settlement talks. If plaintiffs win favorable verdicts, Pfizer may be motivated to negotiate. However, if the defense prevails, settlement values could decrease.
Several factors will affect individual compensation amounts. These include the severity of your meningioma and whether surgery was required. Duration of Depo-Provera use also plays a role. Lost wages, medical expenses, and pain and suffering are considered as well. Each Depo-Provera lawsuit claim is evaluated on its own facts. An experienced attorney can help estimate your potential recovery.
State-by-State Considerations
State tort reform laws can significantly affect your Depo-Provera lawsuit. Each state has its own statute of limitations, damage caps, and filing requirements. For example, some states cap non-economic damages. Others have shorter filing deadlines that could bar your claim entirely.
States with notable plaintiff counts include Florida, Texas, California, Pennsylvania, and New York. Tort reform restrictions vary widely among these states. For instance, Texas has damage caps in certain cases. California generally allows broader recovery for injured plaintiffs. Understanding your state’s specific rules is essential before filing. You can review our state-by-state tort reform guides for more detail on how local laws may affect your claim. Consulting an attorney familiar with your state’s laws is strongly recommended.
Frequently Asked Questions
How long do I have to file a Depo-Provera lawsuit?
The statute of limitations varies by state. It typically ranges from one to six years. However, the discovery rule may extend your deadline in many jurisdictions. The clock often starts when you learned about the connection between Depo-Provera and meningioma. Contact a licensed attorney promptly to protect your rights.
Can I file a Depo-Provera lawsuit if my meningioma was benign?
Yes. Meningiomas are often classified as benign, but they can still cause serious harm. Many plaintiffs in this litigation required brain surgery or experienced debilitating symptoms. A benign diagnosis does not disqualify you from seeking compensation.
What if I stopped using Depo-Provera years ago?
You might still be eligible to file a claim. Meningiomas can develop years after your last injection. As a result, many current plaintiffs stopped receiving the shot long before their diagnosis. What matters is the documented connection between your use and your injury. An attorney can assess your specific situation.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
- DOJ: justice.gov — settlement announcements and press releases
- FDA: fda.gov — drug recalls, warning letters, and safety alerts
- CDC: cdc.gov — health condition data and exposure guidelines
- EPA: epa.gov — environmental contamination data
- Cornell LII: law.cornell.edu — plain-English legal definitions
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.
